APOE and Alzheimer disease: Decline in the Aβ+ groups did not depend on APOE ε4 status in ADNI or BioFINDER; however, in AIBL, little decline was observed in Aβ+ participants who were not also APOE ε4+ (figure 4), as was reported previously.36,37 Evidence for additional risk of cognitive decline for individuals who are both Aβ+ and APOE ε4+ had been incorporated into the design of a phase 2b/3 trial in preclinical AD (clinicaltrials.gov/ct2/show/NCT02569398); however, this pattern was observed in only one of the 3 cohorts studied here.